Home › Funds › BAKER BROS. ADVISORS LP › KNSA

BAKER BROS. ADVISORS LP position in KNSA

KINIKSA PHARMACEUTICALS INTL P ORD SHS CL A · Health Care

BAKER BROS. ADVISORS LP reported holding 2,834,643 shares of KNSA (KINIKSA PHARMACEUTICALS INTL P ORD SHS CL A) in its Q2 2026 13F filing — a position valued at US$181.3M, representing 0.95% of its reported portfolio and ranking #17 among its reported holdings. BAKER BROS. ADVISORS LP has disclosed KNSA holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)2.83M sh
Reported value held$181.28M
Portfolio Weight0.95%
First reportedQ3 2023
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How BAKER BROS. ADVISORS LP's KNSA position evolved

BAKER BROS. ADVISORS LP first disclosed a stake in KNSA in Q3 2023 at 2,809,577 shares (US$48.8M). The position peaked in Q2 2026 at 2,834,643 shares, worth US$181.3M. Across 12 filings, BAKER BROS. ADVISORS LP held the position steady without any share-count change. The most recent filing (Q2 2026) shows 2,834,643 shares valued at US$181.3M.

Quarter by quarter

QuarterSharesValueChange
Q3 2023 2.81M $48.80M New
Q4 2023 2.81M $49.28M Hold
Q1 2024 2.81M $55.43M Hold
Q2 2024 2.82M $52.62M Hold
Q3 2024 2.82M $70.43M Hold
Q4 2024 2.82M $55.75M Hold
Q1 2025 2.82M $62.59M Hold
Q2 2025 2.82M $78.16M Hold
Q3 2025 2.82M $109.68M Hold
Q4 2025 2.83M $116.58M Hold
Q1 2026 2.83M $136.08M Hold
Q2 2026 2.83M $181.28M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About KNSA and 13F data

KNSA (KINIKSA PHARMACEUTICALS INTL P ORD SHS CL A) is a Health Care company. 48 other funds we track also report a position in KNSA — the largest reported positions include Rubric Capital Management LP (US$255.8M), TANG CAPITAL MANAGEMENT LLC (US$144.5M), Spruce Street Capital LP (US$58.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding KNSA

All KNSA fund holders →

FAQ

How long has BAKER BROS. ADVISORS LP held KNSA?

BAKER BROS. ADVISORS LP has disclosed KNSA holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is BAKER BROS. ADVISORS LP's current position in KNSA?

As of Q2 2026, BAKER BROS. ADVISORS LP holds 2.83M shares of KNSA (KINIKSA PHARMACEUTICALS INTL P ORD SHS CL A), valued at $181.28M, representing 0.95% of its reported portfolio and ranking #17.

Has BAKER BROS. ADVISORS LP been buying or selling KNSA?

In the latest 13F filing (Q2 2026), BAKER BROS. ADVISORS LP held unchanged its position in KNSA. The position peaked in Q2 2026 at 2.83M shares.

Which other funds hold KNSA?

Other major institutional holders of KNSA include Rubric Capital Management LP, TANG CAPITAL MANAGEMENT LLC, Spruce Street Capital LP, among 48 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.